Shots:

• As per amended collaboration, Eisai will receive tiered royalties starting at a rate of 2%, rising to 8% if annual sales exceed $1B and will no longer share profits and losses with Biogen on the Aduhelm (aducanumab), effective as of Jan 01, 2023
• Following the tiered royalty model, Eisai will not participate in Aduhelm’s economics beyond royalties. Biogen will solely responsible for decision making and commercialization rights of Aduhelm globally
• Both the companies continue the collaboration on lecanemab without any change in the agreement. The supply agreement related to lecanemab has been extended from 5 to 10 years

Ref: Biogen | Image:Biogen